O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

HA Cryogel article in white 2014

293 visualizações

Publicada em

  • Seja o primeiro a comentar

  • Seja a primeira pessoa a gostar disto

HA Cryogel article in white 2014

  1. 1. HYALURONIC ACID (HA), CRYOGEL, ZERONA WITH ENDYMED’S PURE 3DEEP TECHNOLOGY COMBINATION PROTOCOL! Written By: Noelle Tenaglia Lou Tenaglia November 20, 2014 I (Noelle Tenaglia) have found by incorporating the usage of Hyaluronic Acid (HA) and Cryogel, Zerona with EndyMed’s Pure 3Deep technology helps to increase the effectiveness of this Radio Frequency (RF) ability. By “heating” the area(s) with Zerona and EndyMed along with the application of the HA/Cryogel accelerates the ability to of the above listed technologies to provide more effective results. Research shows Hyaluronic Acid (abbreviated to as HA) and Cryogel cross-linked to be a very effective combination. I have found this effective combination to have multiple applications There is a provided process for preparing a HA cryogel, the process comprising the steps of combining HA, a cross-linking agent and a solvent to form a solution, freezing the solution before the formation of less than 10% of the cross-linking bonds of the cross-linked HA cryogel formed and thawing the solution. Cryogels are a new class of materials with a highly porous structure and having a broad variety of morphologies. Cryogels are produced using a cryotropic gelation technique. Cryotropic gelation (cryogelation or cryostructuration) is a specific type of gel- formation which takes place as a result of cryogenic treatment of the systems potentially capable of gelation. One particular study shows the use of the cryogel as claimed in any one of claims 21 to 26 participants effective for use in the manufacture of a medicament for tissue augmentation, cosmetic surgery, wound dressing, post surgical adhesion prevention, regenerative medicine applications, and tissue engineering applications or for use as a scaffold for the incorporation of cells for tissue repair. 1
  2. 2. Hyaluronic acid (also known as hyaluronan or sodium hyaluronate, and abbreviated to as HA) is a non-sulfated glycosaminoglycan which is distributed widely throughout connective, epithelial, and neural tissues. It is one of the main components of the extracellular matrix, contributes significantly to cell proliferation and migration, and may also be involved in the progression of some malignant tumors. For example, HA is a major component of the synovial fluid and has been found to increase the viscosity of the fluid. Along with lubricant, it is one of the fluid's main lubricating components. HA is an important component of articular cartilage, where it is present as a coat around each cell (chondrocyte). When aggrecan monomers bind to HA in the presence of link protein, large highly negatively charged aggregates form. These aggregates imbibe water and are responsible for the resilience of cartilage (its resistance to compression). The molecular weight (size) of HA in cartilage decreases with age, but the amount increases. HA is also a major component of skin, where it is involved in tissue repair. When skin is excessively exposed to UVB rays, HA acts as a free radical scavenger, absorbing free radicals to degrade. The skin becomes inflamed (sunburn); the cells in the dermis stop producing as much HA and increase the rate of its degradation. HA degradation products also accumulate in the skin after UV exposure. HA is nontoxic, non-immunogenic and biodegradable. HA is degraded by a family of enzymes called hyaluronidases. In humans, there are at least seven types of hyaluronidase-like enzymes, several of which are tumor suppressors. HA derivatives represent an alternative treatment option for the aging face, particularly for facial lines, for lip augmentation and for treatment of distensible atrophic facial scarring. It is known that HA and the like, degrade at low temperature. In particular, it is recommended that hyaluronic acid gels are not frozen in order to avoid structural degradation. As such, there is a prejudice in the art against subjecting HA to low temperatures. It has been found that using the process described above, hyaluronic acid (and its derivatives), can be cross-linked at or below the freezing point of several solvents or solvent systems to provide a cryogel. Surprisingly, contrary to the prejudice in the art, reducing the temperature of the HA during processing to form a cryogel does not result in structural degradation leading to high free HA (un-cross- linked HA). 2
  3. 3. To summarize these findings on the HA/Cryogel has been shown in the studies to be very compatible compounds. However, the cross-linking process of these compounds; which each have there own amazing functionalities, creates an even more effective product. Then I have found by taking this invention of (HA)/Cryogel in the field of biomedical engineering and applying it with my technique with the EndyMed and Zerona technology not only helps to penetrate into the layers of the tissue, increases the ability for skin to tighten, increase skin elasticity, body fat site reduction and fluid reduction on all areas of the body. Specifically my patient,{(X) for HIPPA purposes will remain anonymous}, I found when tightening the frontal neck region that the patient tended to have a lot of fluid build up on upper spinal region. Patient (X) stated reoccurring tension headaches and Migraines with shoulder pain. With the combination treatment of HA/Cryogel, EndyMed, and Zerona I found that this combination was able to reduce the spinal fluid on upper extremities, along with drainage of fluid on the entire spinal column. Conclusion Under the conditions of this study this preliminary result demonstrates the cross-linked Hyaluronic Acid (HA) under cryo-condition (Cryogel) won't have adverse effects on cell growth to show the cell biocompatibility yet combined with Zerona and EndyMed’s Pure 3Deep technology yields sigfinacant results in many areas outside of yet to be studied capabilities. Hyaluronic Acid (HA) and Cryogel combined with provided research has proven capabilities. The technique, product development enhancements, and technology will open a new biomedical along with non-surgical procedure that our findings show with the clinical data yields greater effect that either product or technology can do alone.Various modifications and variations to the described embodiments of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes of carrying out the invention which are obvious to those skilled in the art are intended to be covered by the present invention. 3
  4. 4. Patent Citations Cited Patent Filing date Publication date Applicant Title 1 * Jul 24, 2003 Feb 12, 2004 Jasper Ltd Liability WO2004013182A Co Hyaluronic acid derivatives EP1459772A1 * Dec 13, 2002 Sep 22, 2004 Yasuharu Noishiki Fistula formation-inducing material and body insertion device EP1552839A1 * Aug 16, 2002 Jul 13, 2005 Denki Kagaku Kogyo Kabushiki Kaisha Separate type medical material JP2000248002A * Title not available US20030087850 * Jul 10, 2001 May 8, 2003 Philip Dehazya Gene therapy for dry eye syndrome * Cited by examiner Referenced by Citing Patent Filing date Publication date Applicant Title WO2012112410A 2 * Feb 13, 2012 Aug 23, 2012 Mimedx Group Inc. Micronized placental tissue compositions and methods for making and using the same WO2013021249A 1 Jul 31, 2012 Feb 14, 2013 Glycores 2000 S.R.L. Degradation-resistant cross-linked, low-molecular- weight hyaluronate * Cited by examiner Nov 19th, 2014 Luciano Tenaglia 4